Member Info for CJSterling

Whose paying for the increase in salary.

Executive Directors Dr Vladislav Sandler Total
Basic salary 2020
£’000
200
Basic salary 2019
£’000
145
Pension Total 2020 £’000 2020
5
Pension 2019 £’000
4
£’000
205
Total 2019 £’000
149

LSE if you want to check the above data go to :
https://hemogenyx.com/wp-content/uploads/2020/12/Hemogenyx-Pharmaceuticals-plc-2020-Annual-Report.pdf

Why the Y-O-Y increase?
And why do LSE remove a post stating FACTS which appear in Annual Accounts?
LSE admin, your opportunity to reply?

It must be positive that Vlad has taken a huge increase in salary. Whose paying for that.

What we see here is the divorce bill:
The Company recently received notice that GlobalCo will not in-license the CDX antibody at this juncture, and accordingly gave notice to GlobalCo of its intention to exercise its own option to license GlobalCo's contributions on an exclusive, worldwide basis. As at the date of this document, the Company and GlobalCo are engaged actively in discussions regarding its future development and their respective intellectual property embodied in the final selected clone.

Legal expert but not specialised in risky corporate finance.

Ssccss, my understanding was they were not involved.

HEMO (Vlad) Co Founder and CEO couldn’t see the SP action coming. Why? Cos he thinks he is best man for job, takes no advice and leaves the professionals on the sidelines.
HEMO (Vlad) see no deal coming. Of course.

Surely next update is annual accounts?
Lot of respect for you Tuan, but some
PI’s are so behind the curve. We even have experienced pumpers on other forums stating they have done exhaustive research on Hemo & Vlad and yet they find themselves down 60%. Just highlights the facts that RNS and PR can come contain a large element of exaggeration and no matter what is researched, by whatever self proclaimed expert, nobody knows what the hells going on. Not even the CEO!
All I would say is a leopard ....

Divoc health will require how many for India.

Shift 2m tests and that’s great revenue.

I have never known anyone to use so many caveats..

If you look back over the history of HEMO and Vlad, you will realise that from about August last year there was always doubt that Globalco would licence. Unless you believe the words voiced were actually just the small print..

The mice were light years ahead of the competition. Redmonds words.,

Shardstar message me via Twitter. Happy to advise, but as you will appreciate I won’t publicly state on social media what’s happening as I would be as bad as the perpetrator.

George is funny. Pumpers aren’t.

North of 4p, probably not. If no CLN’s and lower y-o-y loss maybe.
Assume £1m net profit from mice in 2021, what mkt cap could you anticipate from that alone? £6-10m?
Trouble is a diverse product portfolio increases the potential expenditure of HEMO. Focus on the one which will get quick commercial revenue.
Trouble with Vlad and a lot of believers is that they all think:
A. All products are world class and are commercial
B. One product which has a 1 in 250 chance of commercial success is going to transform HEMO by 2022.

They spent the 2020 fundraise quickly dealing with coVid

Wonder if some of the pumpers appear on the payroll or champagne has a separate line in the annual accounts #lifestyle ;-)

That’s why I stated: Sandlers